OBJECTIVE: To elucidate the mechanism of an increase in the albumin levels by daclatasvir (DCV)/asunaprevir (ASV) therapy, we assessed the factors associated with an increase in the albumin levels. METHODS: We retrospectively analyzed 125 patients with chronic hepatitis C virus (HCV) infection, treated with DCV/ASV from November 2014 to January 2016. RESULTS: Albumin levels significantly increased from 4.0 ± 0.4 g/dL at baseline to 4.2 ± 0.4 g/dL at 24 weeks after the end of treatment (EOT) (P < 0.0001) in 108 patients with SVR. Patients with SVR were divided into three groups according to their baseline albumin levels: group A, ≥ 4 g/dL; group B, 3.6-3.9 g/dL; and group C, ≤ 3.5 g/dL. The increase in albumin levels from baseline to at 24 weeks after EOT was significantly larger in group C (0.5 ± 0.5 g/dL, P < 0.0001) and group B (0.2 ± 0.4 g/dL, P = 0.0059) than in group A (0.0 ± 0.3 g/dL). Multivariate analysis showed that aspartate transaminase (AST) levels was the only factor associated with ≥ 0.3 g/dL increase in albumin levels in groups B and C (P = 0.0305). An increase in albumin levels was significantly correlated with a decrease in AST levels (r = 0.4729, P = 0.0119). CONCLUSION: DCV/ASV therapy resulted in an increase in albumin levels in SVR patients, which was significantly correlated with a decrease in AST levels. It is probable that the reduction of inflammation, but not by reduction of fibrosis, mainly caused an increase in albumin levels.
OBJECTIVE: To elucidate the mechanism of an increase in the albumin levels by daclatasvir (DCV)/asunaprevir (ASV) therapy, we assessed the factors associated with an increase in the albumin levels. METHODS: We retrospectively analyzed 125 patients with chronic hepatitis C virus (HCV) infection, treated with DCV/ASV from November 2014 to January 2016. RESULTS: Albumin levels significantly increased from 4.0 ± 0.4 g/dL at baseline to 4.2 ± 0.4 g/dL at 24 weeks after the end of treatment (EOT) (P < 0.0001) in 108 patients with SVR. Patients with SVR were divided into three groups according to their baseline albumin levels: group A, ≥ 4 g/dL; group B, 3.6-3.9 g/dL; and group C, ≤ 3.5 g/dL. The increase in albumin levels from baseline to at 24 weeks after EOT was significantly larger in group C (0.5 ± 0.5 g/dL, P < 0.0001) and group B (0.2 ± 0.4 g/dL, P = 0.0059) than in group A (0.0 ± 0.3 g/dL). Multivariate analysis showed that aspartate transaminase (AST) levels was the only factor associated with ≥ 0.3 g/dL increase in albumin levels in groups B and C (P = 0.0305). An increase in albumin levels was significantly correlated with a decrease in AST levels (r = 0.4729, P = 0.0119). CONCLUSION:DCV/ASV therapy resulted in an increase in albumin levels in SVR patients, which was significantly correlated with a decrease in AST levels. It is probable that the reduction of inflammation, but not by reduction of fibrosis, mainly caused an increase in albumin levels.
Authors: L Serfaty; H Aumaître; O Chazouillères; A M Bonnand; O Rosmorduc; R E Poupon; R Poupon Journal: Hepatology Date: 1998-05 Impact factor: 17.425
Authors: K Kiyosawa; T Sodeyama; E Tanaka; Y Gibo; K Yoshizawa; Y Nakano; S Furuta; Y Akahane; K Nishioka; R H Purcell Journal: Hepatology Date: 1990-10 Impact factor: 17.425
Authors: Anna S Lok; David F Gardiner; Eric Lawitz; Claudia Martorell; Gregory T Everson; Reem Ghalib; Robert Reindollar; Vinod Rustgi; Fiona McPhee; Megan Wind-Rotolo; Anna Persson; Kurt Zhu; Dessislava I Dimitrova; Timothy Eley; Tong Guo; Dennis M Grasela; Claudio Pasquinelli Journal: N Engl J Med Date: 2012-01-19 Impact factor: 91.245
Authors: C Niederau; S Lange; T Heintges; A Erhardt; M Buschkamp; D Hürter; M Nawrocki; L Kruska; F Hensel; W Petry; D Häussinger Journal: Hepatology Date: 1998-12 Impact factor: 17.425
Authors: K Deterding; C Höner Zu Siederdissen; K Port; P Solbach; L Sollik; J Kirschner; C Mix; J Cornberg; D Worzala; H Mix; M P Manns; M Cornberg; H Wedemeyer Journal: Aliment Pharmacol Ther Date: 2015-08-06 Impact factor: 8.171
Authors: Kelley G Núñez; Tyler Sandow; Jai Patel; Mina Hibino; Daniel Fort; Ari J Cohen; Paul Thevenot Journal: Cancers (Basel) Date: 2022-03-25 Impact factor: 6.639
Authors: Reham M Dawood; Mai Abd El-Meguid; Hend Ibrahim Shousha; Ahmed Elsayed; Mohamed Mahmoud Nabeel; Ayman Yosry; Ashraf Abdelaziz; Ghada M Salum Journal: Heliyon Date: 2022-08-08